Diabetes · SGLT2 InhibitorRegulatory Approvalcompetitivemid-term

Centaur Pharmaceuticals submits ANDA for Dapagliflozin

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 12:33:58 AM

Assessment confidence: 91% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Centaur Pharmaceuticals' submission of an ANDA for Dapagliflozin marks a significant entry into the SGLT2 inhibitor market, intensifying competition among existing players. This could lead to shifts in pricing strategies and market dynamics that require close monitoring by portfolio teams. Regulatory context from FDA (FDA TA — DAPAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (18 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of Centaur's entry on market dynamics and pricing strategies for Dapagliflozin. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Diabetes · SGLT2 Inhibitor, 6 regulatory and 2 competitive items passed relevance filtering for Centaur Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (astrazeneca). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This submission indicates Centaur's entry into the competitive landscape of SGLT2 inhibitors, which includes established players like AstraZeneca.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — DAPAGLIFLOZIN (ORIG) (FDA). Entity match (centaur pharmaceuticals); Regulatory pathway relevance (nda). While the ANDA submission is a standard regulatory process, the outcome will influence market access and competitive positioning for Dapagliflozin.

Key Risks

Elevated medium regulatory exposure for Centaur Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a new competitor like Centaur could pressure pricing and market share for established products, potentially affecting revenue streams for companies like AstraZeneca.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Portfolio teams should assess the potential impact of Centaur's entry on market dynamics and pricing strategies for Dapagliflozin.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approvals or market entries by Centaur Pharmaceuticals.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (centaur pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPAGLIFLOZIN (SUPPL)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (dapagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Remotely Delivered Mindfulness-Based Diabetes Education
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Diabetes Care for Breast Cancer Patients
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Genetic Studies of Insulin and Diabetes
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Commercial impact

medium

The entry of a new competitor like Centaur could pressure pricing and market share for established products, potentially affecting revenue streams for companies like AstraZeneca.

Regulatory impact

medium

While the ANDA submission is a standard regulatory process, the outcome will influence market access and competitive positioning for Dapagliflozin.

What to watch

Monitor the FDA's review timeline and any subsequent approvals or market entries by Centaur Pharmaceuticals.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.